CoChat

Combination therapy with GLP ‐1 receptor agonists and basal insulin: a systematic review of the literature

Open access
Balena, R., Hensley, I. E., Miller, S., Barnett, A. H. · 2013 · Diabetes, Obesity and Metabolism
Cited by 142

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Treatment algorithms for type 2 diabetes call for intensification of therapy over time as the disease progresses and glycaemic control worsens. If diet, exercise and oral antihyperglycaemic medications ( OAMs ) fail to maintain glycaemic control then basal insulin is added and ultimately prandial insulin may be required. However, such an intensification strategy carries risk of increased hypoglycaemia and weight gain, both of which are associated with worse long‐term outcomes. An alternative strategy is to intensify therapy by the addition of a short‐acting glucagon‐like peptide‐1 receptor agonist ( GLP ‐1 RA ) rather than prandial insulin. Short‐acting GLP ‐1 RAs such as exenatide twice daily are particularly effective at reducing postprandial glucose while basal insulin has a greater effect on fasting glucose, providing a physiological rationale for this complementary approach. This review analyzes the latest randomized controlled clinical trials of insulin/ GLP ‐1 RA combination therapy and examines results from ‘real‐world’ use of the combinations as reported through observational and clinical practice studies. The most common finding across all types of studies was that combination therapy improved glycaemic control without weight gain or an increased risk of hypoglycaemia. Many studies reported weight loss and a reduction in insulin use when a GLP ‐1 RA was added to existing insulin therapy. Overall, the relative degree of benefit to glycaemic control and weight was influenced by the insulin titration employed in conjunction with the GLP ‐1 RA . The greatest glycaemic benefits were observed in studies with structured titration of insulin to glycaemic targets while the greatest weight benefits were observed in studies with a protocol‐specified focus on insulin sparing. The adverse event profile of GLP ‐1 RAs in the reviewed trials was similar to that reported with GLP ‐1 RAs as monotherapy or in combination with OAMs with gastrointestinal events being the most commonly reported.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12025

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 142

Metadata

Authors
Balena, R., Hensley, I. E., Miller, S., & Barnett, A. H.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2012-11-12
Volume
15
Issue
6
Pages
485-502
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2033283875
Cited by
142
References
16
FWCI
1.94
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.